Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC.

e21231Background: Osimertinib (osi) is a potent, CNS-penetrant 3rd-generation EGFR TKI. Though older TKIs did not add benefit to chemo (IMPRESS, Soria et al 2015), combining osi with chemo to prolo...